Skip to content

Monte Rosa Therapeutics

US · GLUE #3350 by market cap Listed 2021
8.64 -0.27 -3.03%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 8.74 -1.91%
After-hours 8.64 0.00%
Overnight 8.83 -0.90%
24.568.648.642026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on GLUE?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -38.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 24.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D

How much profit the business keeps from each dollar of sales and capital.

Operating margin -43.8% Better than 9%
Net margin -31.2% Better than 11%
Return on equity -16.9% Better than 17%
Return on invested capital -19.0% Better than 14%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -39.6% Better than 11%
6-month return -54.1% Better than 6%
12-month return (ex latest month) -23.8% Better than 13%
Distance below 52-week high 66.5% Better than 8%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.1x Better than 89%
Debt to assets 8.7% Better than 72%
Interest coverage -7,739.0x Better than 1%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 191.0% Better than 94%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.79%
1M -23.94%
3M -41.54%
6M -53.67%
YTD -44.90%
1Y -36.09%
3Y +165.85%
5Y -55.85%

Key statistics

Price & volume

Prev close
8.91
Open
8.73
Day range
8.48 - 9.04
Avg price
8.67
Volume
2.52M
Turnover
21.85M
Amplitude
6.29%
52-week range
8.48 - 25.77

Valuation

P/E
-18.78
P/E (TTM)
-6.22
P/B
1.49
EPS
-0.46
Net profit
-39.31M
Net assets
496.21M

Share structure

Market cap
738.29M
Float cap
491.52M
Shares out
85.45M
Float shares
56.89M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-06-24
52-week range 1% of range
8.48 25.77

66.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-10.84M net over the window

Short interest

Shares short
20.86M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Monte Rosa Therapeutics (GLUE)?

Monte Rosa Therapeutics last traded at 8.64. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Monte Rosa Therapeutics's market cap?

About 738.29M.

What is the P/E ratio of Monte Rosa Therapeutics?

The trailing twelve-month P/E is -6.22, below its own 5-year average of 2.60 — toward the bottom of its historical range (11.09% percentile). See the Valuation tab for the full history.

Does Monte Rosa Therapeutics pay a dividend?

Monte Rosa Therapeutics does not currently pay a regular dividend.

Is Monte Rosa Therapeutics a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 25.14, which implies 191.0% upside from the current price. This is not investment advice.

What is Monte Rosa Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Monte Rosa Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Monte Rosa Therapeutics discussion 0 comments

Add a comment